More therapeutics that work? I thought the Emergency Use Authorization for vaccines was ONLY approved because there were no therapeutics. Now it appears that we have several confirmed therapeutics. At what point does this negate the EUA?
Researchers at the University of Toronto have created chemical compounds that can neutralize SARS-CoV-2 and several of its variants.
In a recent paper published in the Journal of Medicinal Chemistry, the researchers report the creation of D-peptides that neutralize the virus and stop infection of cultured human cells.
Known as mirror-image peptides, the compounds have chemical properties that make them suitable for the development of low-cost antiviral therapeutics.
“A big advantage of mirror-image peptides is their long stability and that they are relatively cheap to produce,” says Philip Kim, senior author of the study and a professor of molecular genetics and computer science at the Donnelly Centre for Cellular and Biomolecular Research at U of T’s Temerty Faculty of Medicine.
“You could imagine them being formulated as a nasal spray to take prophylactically to prevent infection from occurring.”>
We already have this with Aviptadil, of course, the FDA is sitting on its EUA application since May even though it has a p-value of .0001 for stopping replication and healing the lungs
U of T researchers didn't kill themselves.
More therapeutics that work? I thought the Emergency Use Authorization for vaccines was ONLY approved because there were no therapeutics. Now it appears that we have several confirmed therapeutics. At what point does this negate the EUA?
I think this should be stickied
In a recent paper published in the Journal of Medicinal Chemistry, the researchers report the creation of D-peptides that neutralize the virus and stop infection of cultured human cells.
Known as mirror-image peptides, the compounds have chemical properties that make them suitable for the development of low-cost antiviral therapeutics.
“A big advantage of mirror-image peptides is their long stability and that they are relatively cheap to produce,” says Philip Kim, senior author of the study and a professor of molecular genetics and computer science at the Donnelly Centre for Cellular and Biomolecular Research at U of T’s Temerty Faculty of Medicine.
“You could imagine them being formulated as a nasal spray to take prophylactically to prevent infection from occurring.”>
We already have this with Aviptadil, of course, the FDA is sitting on its EUA application since May even though it has a p-value of .0001 for stopping replication and healing the lungs